KAUST researchers led by Dr. Niveen Khashab have developed thermosensitive liposomes for controlled drug release, particularly in cancer therapies. The liposomes are designed to release drugs only when they reach heated tumor tissue, minimizing systemic side effects. Cholesterol moieties are used as anchors to create a "nail" or "comb" effect, enabling temperature-triggered drug release inside cells. Why it matters: This targeted drug delivery system could significantly improve the efficacy and reduce the toxicity of cancer treatments.
A KAUST team discovered a simple method to fabricate microspheres using block copolymer self-assembly. The resulting particles have pH-responsive gates and a highly porous structure, granting them ultrahigh protein sorption capacity. The team leveraged their expertise in block copolymers and self-assembly to achieve this. Why it matters: This new method and the resulting particles have potential applications in biotechnology, medicine, and catalysis, advancing materials science in the region.
KAUST researchers are developing a streamlined COVID-19 diagnostic testing method using superparamagnetic nanoparticles (MNPs). The team, led by Assistant Professor Mo Li, aims to address reagent shortages and improve automation by creating an in-house extraction kit compatible with inactivated samples. Associate Professor Samir Hamdan identified a protocol for making silica-coated MNPs that survive inactivation reagents, enabling magnetic separation without centrifugation. Why it matters: This innovation could significantly increase testing capacity in Saudi Arabia and globally by reducing biosafety risks, reagent dependence, and manual processing.
KAUST startup uODS signed an MoU with Saudi Aramco Base Oil Company (Luberef) to develop and deploy technology removing sulfur from hydrocarbons. The uODS process, based on KAUST's sonochemistry research, reduces sulfur in marine fuels to meet IMO 2020 regulations. Luberef aims to reduce its environmental footprint by piloting the uODS technology at its Jeddah refineries, with uODS set to produce 10 tons per day of desulfurized fuel for testing. Why it matters: The partnership demonstrates KAUST's role in addressing Saudi Arabia's environmental goals and showcases the potential of university spin-offs to contribute to a more sustainable oil industry in the region.
KAUST startup Quantum Solutions manufactures quantum dots, semiconducting nanoparticles that emit light with controllable energy. These dots are being explored for applications including displays, photodetectors, and solar cells. Quantum dots can enhance the efficiency of silicon solar panels by absorbing infrared light. Why it matters: This highlights the potential of KAUST-incubated startups to contribute to advanced materials science and renewable energy technologies in the region.
KAUST Research Scientist Dr. Ram Karan received a Young Scientist Award at the 15th International Congress on Thermophiles in Japan for his work on extremozymes from Red Sea brine pools. His research focuses on identifying, purifying, and bioengineering microbial proteins from these pools. He utilizes single-amplified genomes (SAGs) to produce extremozyme proteins without needing to grow cells in the lab. Why it matters: This award recognizes KAUST's innovative research into extremophiles, which have the potential to develop novel, sustainable biotechnical processes for industrial applications.
KAUST research scientist Dr. Ram Karan won two awards at the International Congress of Extremophiles 2018 for his work on extremozymes from Red Sea brine pools. His research focuses on understanding how life is possible under extreme conditions using culture-independent methods to evaluate the structure and function of polyextremophilic enzymes. Crystal structure analysis provided insights into how enzymes adapt to extreme conditions. Why it matters: This research provides insights into the possibilities of life in extreme conditions and has implications for astrobiology.
Researchers at KAUST and Peking University Third Hospital have created a novel blastoid model for studying early human development using extended pluripotent stem cells (EPSCs). The blastoid is a 3D cell model mimicking the blastocyst phase, avoiding ethical concerns associated with using human embryos. The team showed that blastoids can be cultured to mimic post-implantation development, offering insights into early cell lineages. Why it matters: This innovation provides a way to study human embryogenesis without the ethical constraints of using actual embryos, potentially advancing our understanding of miscarriage and birth defects.